Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, posted on X:
“BIG BTC Update from ASCO25.
The GAIN trial (Phase III) in resectable BTC (ICC/ECC/GBC) tested:
- Arm A: Perioperative Gem+Cis
- Arm B: Upfront surgery + adjuvant chemo
Here’s what they found: mOS:
- Arm A = 27.8 mo
- Arm B = 14.6 mo
HR 0.46 [0.22–0.96]; p = 0.04 R0 resection rate:
- Arm A = 62.5%
- Arm B = 33.3%
Postop mortality (30-day):
- Arm A = 4.2%
- Arm B = 24%
- No increase in toxicity
- Lower periop deaths
- Higher curative resections
Conclusion: Neoadjuvant Gem+Cis nearly doubled survival and improved surgery outcomes in BTC!
Game-changer for localized disease?”
More posts featuring Amol Akhade on OncoDaily.